Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Entinostat Combined With Chemotherapy as Second-line Therapy for Unresectable Locally Advanced or Metastatic Bladder Cancer: A Single-arm, Prospective Clinical Trial

NCT07261592 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.

NCT NCT07261592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07261592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Entinostat Combined With Chemotherapy as Second-line Therapy for Unresectable Locally Advanced or Metastatic Bladder Cancer: A Single-arm, Prospective Clinical Trial
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
April 30, 2029
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, chemotherapy, entinostat, histone deacetylase inhibitor